2015. Erlotinib as Second-Line Therapy for Patients with Advanced Non-Small-Cell Lung Cancer and Wild-Type EGFR Tumors. Journal of Analytical Oncology. 4, 3 (Jun. 2015),  94–101. DOI:https://doi.org/10.6000/1927-7229.2015.04.03.1.